- Email:
Astrocyte Differentiation Service
Introduction
Astrocyte Differentiation directs human pluripotent stem cells into functional glial cells. Astrocytes regulate neuroinflammation and metabolic homeostasis, and their dysfunction is closely linked to CNS disorders. Creative Biolabs generates regionally specified, functionally mature astrocytes via precision patterning and strict quality control. These cells recapitulate A1/A2 polarization and disease-related phenotypes, providing reliable and high-fidelity in vitro models for CNS drug discovery, toxicity testing, and target validation.
Discover How We Can Help - Request a Consultation
Astrocyte Differentiation Service
Astrocytes are the most abundant glial cells in the central nervous system, participating in synaptic formation, neuronal support, ion homeostasis, and blood-brain barrier maintenance. Dysfunction and reactivity of astrocytes are closely associated with neurodegenerative diseases, neuroinflammation, stroke, epilepsy, and psychiatric disorders.
Fig. 1 The role of astrocytes in neurological diseases.1,3
Key Features
- Derived from human iPSCs/ESCs under defined, xeno-free, feeder-free conditions
- Uses optimized small-molecule induction for efficient astrocyte specification
- Generates mature, functional GFAP+ AQP4+ S100β+ astrocytes with high purity
- Shows typical star-like morphology and non-tumorigenic properties
- Stable batch consistency and suitable for long-term culture
Service Content
- Differentiation from pluripotent stem cells to neural progenitor cells
- Directed differentiation and maturation into functional astrocytes
- Inflammatory activation model (A1/A2 phenotype induction) available
- Quality validation: immunofluorescence, qPCR, Western blot
- Optional: glutamate uptake assay, co-culture with neurons, cytokine detection
Related Diseases & Mechanisms
| Disease | Mechanism Involving Astrocytes |
|---|---|
| Alzheimer's Disease | Astrogliosis, synaptic dysfunction, Aβ clearance impairment |
| Parkinson's Disease | Inflammatory activation, neurotoxic factor release |
| ALS/SMA | Astrocyte-mediated neurotoxicity, impaired support |
| Stroke / Ischemia | Ischemic reactivity, blood-brain barrier damage |
| Autism & Epilepsy | Abnormal synaptic regulation and ion homeostasis |
Applications
- Neurological disease modeling and mechanism research
- High-throughput drug screening and neuroprotective evaluation
- Glia-neuron interaction and synaptic function studies
- Neuroinflammation and reactive astrocyte research
- Toxicity testing and target validation for CNS drug discovery
Workflow
The differentiation process at Creative Biolabs is a highly orchestrated technical journey designed to preserve lineage identity and functional responsiveness.
What We Can Offer
At Creative Biolabs, we provide a robust, industrial-scale platform for Astrocyte Differentiation that bridges the gap between basic research and large-scale pharmaceutical applications. We offer:
Customized Differentiation Programs
Fully tailored protocols to generate astrocytes from your specific patient-derived iPSC lines or our extensively characterized bank.
Scale-Up Capabilities
Seamless transition from laboratory-scale pilot batches to large-scale production, ensuring consistency across high-throughput screening campaigns.
Strict Quality Assurance
Documentation quality and procedures for iPSC origin and astrocyte purity are assessed and approved by our internal Quality-by-Design (QbD) framework.
Codon & Genetic Optimization
Expert CRISPR/Cas9 services to optimize or introduce disease-relevant mutations before differentiation to facilitate specific expression profiles.
High-Standard Analytical Tools
Integrated use of Process Analytical Techniques (PAT) to quantify and evaluate the quality, metabolic flux, and polarization state of every batch.
Strict Aseptic Verification
Following the basic principles of Good Manufacturing Practice (GMP) to ensure all cellular products are free from mycoplasma and contaminants.
Advanced Functional Validation
Detailed characterization of the "A1/A2" inflammatory switch and mitochondrial electron transport chain integrity (OCR/ECAR) as standard deliverables.
Experience the Creative Biolabs Advantage - Get a Quote Today
Case Study
A study focused on ABCD1 mutations causing ALDP deficiency as the key mechanism. A SMADi‑based three‑step protocol was used to differentiate control, AMN, and cALD patient iPSCs into mature astrocytes, which were characterized by immunofluorescence, Western blotting, and lipid profiling. The results showed that all iPSC lines efficiently differentiated into mature astrocytes positive for GFAP, AQP4, S100β, and EAAT1 and negative for A2B5. ABCD1 mutations did not affect astrocyte differentiation potential.
Fig.2 Using iPSC-derived astrocytes to construct a model that simulates the phenotype of X-linked adrenoleukodystrophy.2,3
Customer Reviews
FAQs
Q: How is regional specificity maintained during long-term culture?
A: We use active lineage tracing and regionalized neural induction protocols that prevent the common drift toward non-specific "default" cortical identities.
Q: What functional markers do you use to verify maturity?
A: We go beyond GFAP; we verify maturity through S100β, EAAT1/2, ALD1H1, and functional glutamate uptake assays.
Q: Can you model specific disease phenotypes like A1-reactive astrocytes?
A: Yes, we can provide pre-polarized A1 or A2 astrocytes or provide the optimized induction protocols for your in vitro assays.
Q: Are these astrocytes compatible with Blood-Brain Barrier (BBB) models?
A: Yes. Our astrocytes are matured to support tight junction formation and are ideal for BBB-on-a-chip applications.
Q: How do I initiate a custom differentiation project?
A: You can provide your own iPSC lines or select from our characterized control/disease bank to start the 10-14 week differentiation process.
Creative Biolabs provides full-scale solutions for neurodegenerative disease modeling and therapeutic validation. Our team is ready to customize a differentiation protocol that meets your exact research needs.
Contact Our Team for More Information and to Discuss Your Project
References
- Kaur, Navtej, and Jaspreet Singh. "Generation and characterization of human iPSC-derived astrocytes with potential for modeling X-linked adrenoleukodystrophy phenotypes." International Journal of Molecular Sciences 26.4 (2025): 1576. https://doi.org/10.3390/ijms26041576.
- Huang, Meihui, et al. "Astrocyte in neurological disease: pathogenesis and therapy." MedComm 6.8 (2025): e70299. https://doi.org/10.1002/mco2.70299.
- Distributed under Open Access license CC BY 4.0, without modification.
For Research Use Only. Not For Clinical Use.